Qinec Appoints Jim Horsburgh as Chairman - Gilde Healthcare

Qinec Appoints Jim Horsburgh as Chairman

7 december 2015

Industry veteran joins digital health company

LONDON – Qinec, a digital health company focused on cloud based Personalised Healthcare Management, today announced that healthcare IT veteran Jim Horsburgh has joined Qinec’s board as a non executive member and been appointed as independent chairman.

Robbie Hughes, CEO at Qinec said:

“Qinec’s Personalised Healthcare Management platform has been adopted by many of the UK’s largest commercial healthcare providers. Jim’s expertise as a chairman of numerous digital health companies will be invaluable in guiding Qinec through the next stage of growth.”

Jim previously served as Chairman of healthcare IT company System C, leading the company through its successful IPO and acquisition by McKesson. He also served as SVP Worldwide Marketing at Visio through its IPO and acquisition by Microsoft, and in business development and marketing roles at CentralPoint Software, Lotus and Olivetti. Jim currently serves as chairman for Insource, a data warehousing automation solution specialising in healthcare, and chairman for Shearwater, a developer of mobile solutions for healthcare. He’s previously served as chairman for ScriptSwitch Ltd. and Triaster Ltd.

Jim Horsburgh said:

“Qinec has had a huge impact on healthcare, challenging the legacy, siloed mentality of healthcare IT by focusing its approach on the orchestration of the patient journey. Qinec has established itself as a trusted agent of change within the industry; its proposition is compelling for patients, providers and payers alike.”

About Qinec

Qinec is a UK-based digital health company providing Personalized Healthcare Management (PHM) solutions. The company’s cloud-based SaaS platform uses real time data to orchestrate the patient journey to achieve optimal outcomes for patients, providers and payers at lower cost. Managing millions of patients a year across Europe, Qinec tailors processes and optimizes clinical and administrative workflows across every specialty of outpatient care. For more information about Qinec please visit www.qinec.com.

Press Contact:

Michele Moore
PR Manager
+44 07507 246 961
Michele.Moore@qinec.com

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025